CK Life Sciences Int'l (Holdings) Inc 2017 AR2
The report highlights CK Life Sciences' financial and operational performance for the year ended December 31, 2017, during which the company achieved a profit attributable to shareholders of HK$258 million. In the agriculture-related segment, the company completed the acquisition of the remaining 50% share of salt field operations in New Zealand, strategically focusing on stable, cash-generative salt production. The nutraceutical business saw steady performance, with Lipa Pharmaceuticals being named 'High Quality Manufacturer of the Year' for the fourth consecutive year. Additionally, the company progressed its pharmaceutical R&D initiatives, including Polynoma's Phase III clinical trial for a melanoma vaccine and WEX Pharma's pain management clinical trials.
Company: CK Life Sciences Int'l (Holdings) Inc
Sector: Manufacturing
Country: Hong Kong
Year: 2017
Type: AR2
Pages: 184
Back to company
CK Life Sciences Int'l (Holdings) Inc
Annual Report
The report highlights CK Life Sciences' financial and operational performance for the year ended December 31, 2017, during which the company achieved a profit attributable to shareholders of HK$258 million. In the agriculture-related segment, the company completed the acquisition of the remaining 50% share of salt field operations in New Zealand, strategically focusing on stable, cash-generative salt production. The nutraceutical business saw steady performance, with Lipa Pharmaceuticals being named 'High Quality Manufacturer of the Year' for the fourth consecutive year. Additionally, the company progressed its pharmaceutical R&D initiatives, including Polynoma's Phase III clinical trial for a melanoma vaccine and WEX Pharma's pain management clinical trials.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2017
Reporting Period
Jan 1, 2017 - Dec 31, 2017
Fiscal Year
2017
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Materiality Assessment
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Energy Consumption
Water Consumption
Employees